Coordinatore | THE BABRAHAM INSTITUTE
Organization address
address: Babraham Hall contact info |
Nazionalità Coordinatore | United Kingdom [UK] |
Totale costo | 14˙620˙568 € |
EC contributo | 11˙000˙000 € |
Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
Code Call | FP7-HEALTH-2009-two-stage |
Funding Scheme | CP-IP |
Anno di inizio | 2010 |
Periodo (anno-mese-giorno) | 2010-04-01 - 2015-03-31 |
# | ||||
---|---|---|---|---|
1 |
THE BABRAHAM INSTITUTE
Organization address
address: Babraham Hall contact info |
UK (CAMBRIDGE) | coordinator | 823˙536.00 |
2 |
KUNGLIGA TEKNISKA HOEGSKOLAN
Organization address
address: Valhallavaegen 79 contact info |
SE (STOCKHOLM) | participant | 1˙909˙515.00 |
3 |
UNIVERSITAET ZUERICH
Organization address
address: Raemistrasse 71 contact info |
CH (ZURICH) | participant | 1˙125˙484.00 |
4 | KOBENHAVNS UNIVERSITET | DK | participant | 727˙600.00 |
5 |
LUNDS UNIVERSITET
Organization address
address: Paradisgatan 5c contact info |
SE (LUND) | participant | 695˙742.00 |
6 |
UPPSALA UNIVERSITET
Organization address
address: SANKT OLOFSGATAN 10 B contact info |
SE (UPPSALA) | participant | 670˙293.00 |
7 |
TECHNISCHE UNIVERSITAT BRAUNSCHWEIG
Organization address
address: POCKELSSTRASSE 14 contact info |
DE (BRAUNSCHWEIG) | participant | 565˙664.00 |
8 |
DEUTSCHES KREBSFORSCHUNGSZENTRUM
Organization address
address: Im Neuenheimer Feld 280 contact info |
DE (HEIDELBERG) | participant | 540˙358.00 |
9 |
VIB
Organization address
address: Rijvisschestraat 120 contact info |
BE (ZWIJNAARDE - GENT) | participant | 505˙473.00 |
10 |
TEKNOLOGIAN TUTKIMUSKESKUS VTT
Organization address
address: TEKNIIKANTIE 4 A contact info |
FI (ESPOO) | participant | 459˙007.00 |
11 |
EUROPEAN MOLECULAR BIOLOGY LABORATORY
Organization address
address: Meyerhofstrasse 1 contact info |
DE (HEIDELBERG) | participant | 454˙400.00 |
12 |
UNIVERSITAET KASSEL
Organization address
address: MONCHEBERGSTRASSE 19 contact info |
DE (KASSEL) | participant | 426˙579.00 |
13 |
UNIVERSITA DEGLI STUDI DI ROMA TOR VERGATA
Organization address
address: VIA ORAZIO RAIMONDO 18 contact info |
IT (ROMA) | participant | 398˙282.00 |
14 |
PARATOPES LIMITED
Organization address
address: WOODFALL AVENUE 62 BARNET contact info |
UK (LONDON) | participant | 390˙284.00 |
15 |
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Organization address
address: GESCHWISTER-SCHOLL-PLATZ contact info |
DE (TUEBINGEN) | participant | 374˙014.00 |
16 |
KAROLINSKA INSTITUTET
Organization address
address: Nobels Vag 5 contact info |
SE (STOCKHOLM) | participant | 290˙763.00 |
17 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Organization address
address: University Offices, Wellington Square contact info |
UK (OXFORD) | participant | 290˙763.00 |
18 |
BABRAHAM BIOSCIENCE TECHNOLOGIES LIMITED
Organization address
address: Babraham Hall contact info |
UK (CAMBRIDGE) | participant | 220˙672.00 |
19 |
HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
Organization address
address: Ingolstaedter Landstrasse 1 contact info |
DE (MUENCHEN) | participant | 131˙571.00 |
20 |
The Structural Genomics Consortium
Organization address
address: Euston Road 215 contact info |
UK (London) | participant | 0.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'The Affinomics programme aims to leverage existing efforts in Europe to generate large-scale resources of validated protein-binding molecules (‘binders’) as affinity reagents for characterisation of the human proteome and to apply them in comprehensive structural and functional analyses of protein expression, interactions and complexes. Proteome targets will be focused on five categories of inter-related human proteins involved in signal transduction, cell regulation and cancer, namely protein kinases, SH2 domain-containing proteins, protein tyrosine phosphatases, proteins somatically mutated in cancers and candidate cancer biomarkers. Binders to about 1000 protein targets will be made over the course of the programme. A high throughput, coordinated production pipeline for antigens and binders will be established. Target antigens will be expressed in three forms, as folded full-length proteins or domains, as large peptide fragments (PrESTs) based on low homology to other human proteins and as small peptides, in some cases phosphorylated. Binder types to be generated include affinity-purified polyclonal antibodies, monoclonal antibodies, recombinant antibody fragments and non-immunoglobulin scaffolds. An important aspect will be the development of highly efficient ‘next generation’ recombinant selection methods, based on phage, cell and ribosome display, capable of producing high quality binders at greater throughput and lower cost than hitherto. Systems and procedures for thorough binder validation and quality control will be established. The affinity reagents will be applied in advanced innovative and sensitive technologies for specific detection of target proteins and interacting protein complexes in cells, tissues and fluids, for improved understanding of protein function and new classes of diagnostic assays.'
European researchers are building a database of functional proteins and their specific binders. With widespread applications in characterisation of the human proteome, biotech and biomedicine, the scope of the AFFINOMICS project is enormous.